Clinical and Histopathologic Characteristics of BAP1 Mutations
Status: | Active, not recruiting |
---|---|
Conditions: | Lung Cancer, Skin Cancer, Liver Cancer, Cancer, Cancer |
Therapuetic Areas: | Oncology |
Healthy: | No |
Age Range: | 18 - Any |
Updated: | 3/3/2019 |
Start Date: | January 2013 |
End Date: | January 2020 |
The goal of this protocol is to determine the prevalence of somatic and germline mutations in
BAP1 (BRCA associated protein-1) among patients with mesothelioma , choroidal nevus, primary
uveal melanoma (UM), or metastatic UM seen at our institution.
BAP1 (BRCA associated protein-1) among patients with mesothelioma , choroidal nevus, primary
uveal melanoma (UM), or metastatic UM seen at our institution.
Inclusion Criteria:
All consents:
- > or = to 18 years of age
- Ability to provide informed consent
Consent 1:
Mesothelioma
- Histologically proven diagnosis of Mesothelioma OR Choroidal nevus
- Diagnosis of choroidal nevus by direct examination and/or ultrasound/optical coherence
tomography and possibly fluorescein angiography OR Primary uveal melanoma
- Diagnosis of uveal melanoma by direct examination and/or ultrasound/optical coherence
tomography and possibly fluorescein angiography
Consent 2:
Mesothelioma
- Histologically proven diagnosis of Mesothelioma AND
- BAP1 mutation or loss of expression identified in tumor sample
OR one of the following:
- Age<50 at diagnosis
- No history of asbestos exposure
- Personal history of choroidal nevus, uveal melanoma, melanoma, renal cell carcinoma,
or cholangiocarcinoma
- Family history of choroidal nevus, uveal melanoma, mesothelioma, renal cell carcinoma,
or cholangiocarcinoma
- History of malignancy in more than two first-degree relatives OR Choroidal nevus
- Diagnosis of choroidal nevus by direct examination and/or ultrasound/optical coherence
tomography and possibly fluorescein angiography AND one of the following:
- More than one clinical risk factor, which may include: orange pigment, thickness > 1 <
2.5mm
- Personal history of uveal melanoma, skin melanoma, mesothelioma renal cell carcinoma,
or cholangiocarcinoma
- Family history of choroidal nevus, uveal melanoma, mesothelioma renal cell carcinoma,
or cholangiocarcinoma OR Primary uveal melanoma
- Diagnosis of uveal melanoma by direct examination and/or ultrasound/optical coherence
tomography and possibly fluorescein angiography
AND one of the following:
- Personal history of uveal melanoma, skin melanoma, mesothelioma, renal cell carcinoma,
or cholangiocarcinoma
- Family history of choroidal nevus, uveal melanoma, mesothelioma, renal cell carcinoma,
or cholangiocarcinoma
- History of malignancy in more than two first-degree relatives OR Metastatic uveal
melanoma
- Histologically proven diagnosis of metastatic uveal melanoma AND
- BAP1 mutation or loss of expression identified in tumor sample
OR one of the following:
- Personal history of uveal melanoma, skin melanoma, mesothelioma renal cell carcinoma,
or cholangiocarcinoma
- Family history of choroidal nevus, uveal melanoma, mesothelioma renal cell carcinoma,
or cholangiocarcinoma
- History of malignancy in more than two first-degree relatives
Consent 3:
- Relative of patient with germline BAP1 mutation identified through identified testing
Exclusion Criteria:
We found this trial at
2
sites
500 Westchester Avenue
Harrison, New York 10604
Harrison, New York 10604
Phone: 646-888-4656
Click here to add this to my saved trials
1275 York Ave
New York, New York 10021
New York, New York 10021
(212) 639-2000
Principal Investigator: Marjorie Zauderer, MD
Phone: 646-888-4656
Memorial Sloan Kettering Cancer Center Memorial Sloan Kettering Cancer Center — the world's oldest and...
Click here to add this to my saved trials